FDA Proposes Guidelines to Decrease Animal Testing for Cancer Drug Development

The U.S. Food and Drug Administration has released new draft guidance aimed at reducing the reliance on animal testing for nonclinical safety assessments of certain cancer medications. This initiative seeks to streamline the drug development process and potentially expedite the availability of new treatments. The recommendations include using fewer animal species or replacing animal studies with alternative evidence-based methods.